Hisamitsu Pharmaceut (HTSUF) 39.6000 $HTSUF Restless

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2015 at 10:51 AM

Hisamitsu Pharmaceut (HTSUF) 39.6000 $HTSUF

Restless Legs Syndrome Therapeutics Pipeline Review 2015 - 7 Companies & 7 Drug Profiles
M2 - Wed Mar 11, 7:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqjzpr/restless_legs) has announced the addition of the "Restless Legs Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Ascendis Pharma A/S - Hisamitsu Pharmaceutical Co., Inc. - Ligand Pharmaceuticals, Inc. - Omeros Corporation - Purdue Pharma L.P. - Serina Therapeutics, Inc. Drug Profiles - (naloxone hydrochloride oxycodone hydrochloride) ER - ACP-006 - aplindore fumarate - AZ-008 - OMS-527 - ropinirole hydrochloride - SER-214 For more information visit http://www.researchandmarkets.com/research/mq...tless_legs
ASND: 18.05 (unch), ALXA: 1.99 (+0.01), OMER: 24.58 (+0.44)

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 5.70 (+0.20), PFE: 35.44 (+0.41), SUPN: 12.84 (+0.34), LLY: 73.92 (+1.56), DRRX: 1.98 (+0.08), NDRM: 13.93 (-0.25), SHPG: 248.77 (-5.55), ITCI: 23.98 (+0.15)

Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
ABT: 47.15 (+0.15), NVO: 55.94 (+1.34), TXMD: 6.63 (+0.01), ANIP: 68.23 (-1.34), MRK: 57.25 (-0.18), AMGN: 163.38 (+1.89), TEVA: 66.37 (-0.77), NVS: 103.58 (+1.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Birth Registration Revolution: OSIA Interoperability Demo

Bringing Birth Registration into the 21st Century Alright, let's cut through the fog. If you ask most folks about their birth certificates, you'd hear tales of tattered paper and government office runs. What if I told you this vital piece of paper could be reborn altogether? That's what the Secure Identity Alliance is up to with their OSIA Live Interoperability Demo at...

MCAP's Q3 Earnings: Sizing Up the Tech Game

Quarterly Results: The Numbers to Watch Alright, here's the scoop from MCAP Inc.: they just tossed their hat in the quarterly earnings ring, flexing a third quarter EPS of $0.15 a share. Not exactly champagne-popping numbers, but hey, let's not throw out the party favors just yet. Revenues rolled in at a neat $26.7 million, with EBITDA tagging along at $5.2 million. So,...

Truelink's Strategic Expansion: GES Acquires CSG Creative

Truelink's Big Move in Creative Marketing I don't throw around the word 'synergy' lightly, but this Truelink Capital move has me grudgingly utter it. Picture this: GES, a big dog in event marketing, just grabbed CSG Creative, a firm with its teeth sunk deep into association and event organizer marketing. It sounds like the kind of match you only find lurking in the fancy...

ACR Poker's $20M OSS Leads High-Stakes Weekend

Sunday Showdown at ACR: A Massive Poker Feast Kicking off the action on November 8, ACR Poker brings its Online Super Series (OSS) into the spotlight, and listen up—there's a cool $20 million spread on the table through November 24. What's got people really tuned in, though, is the mix of big stakes, high tension events, and a shot at paradise over in the Bahamas....

Maxwell M1 Hybrid Unveils Game-Changing Aircraft

Welcome to the Future of Amphibious Flight You ever wonder when we'd get past seeing traditional planes stuck at runways? Well, Maxwell Aircraft just fired a hefty shot across the bow with their M1 Hybrid amphibious model. This ain't your run-of-the-mill crate with wings; it's redefining what these birds can do, particularly if you're eyeing remote areas or water-based...

CMS 2027 Fee Schedule: Game Changer for SI Joint Procedures

CMS's Move: A New Payment Pathway You don't expect bureaucrats to stir things up, but check this out: the CMS 2027 Physician Fee Schedule has done just that by setting a non-facility (office) payment rate for CPT code 27279. This code covers those fiddly, minimally invasive sacroiliac (SI) joint procedures, where you engage bone and get down to real orthopedic business....

Expansive Moves to Salt Lake City for Flexible Growth

Breaking New Ground in Utah Alright, letting another workspace provider muscle into a new territory isn't groundbreaking anymore, but with Expansive breaking into Salt Lake City, there's more than meets the eye. We're talking about expanding not just geographically but also strategically in Utah's fertile grounds—characterized by a booming local economy and escalating...

Key Questions Before Investing in Oil & Gas Ventures

Navigating Oil and Gas with Kevin K. Thibeau Investors, buckle up. The world of oil and gas ain't for the faint-hearted! We’re talking about an industry that, when you strike it right, can flow like a Texas gusher—but a misstep can leave your portfolio drier than the Mojave. Kevin K. Thibeau, the commander at Wheeler Resource Recovery since back in 2014, lays out the...

Ajman Media Forum 2026: Shaping the Future of Media

Kicking Off Ajman's Media Innovation Push Forget the stale conferences; Ajman is putting its chips on the table with the inaugural Ajman Media Forum 2026. Set to ignite on November 18 and 19 under the catchy theme 'Who Owns the Signal?,' this two-day brain fest takes media transformation by the horns. They're not just talking; they're set to weave emerging tech,...

QORAI CORP's Q4 Nexus: A New AI Frontier

Breakthrough in AI: Enter Q4 Nexus It's not every day you see a tech player emerge with something genuinely fresh—QORAI CORP is shaking up the scene with its Q4 Nexus platform. This isn't just another AI model upgrade. We're talking about a rethink of the very architecture we rely on to power these systems. Founder Robby Joshi's brainchild, Q4 Nexus, jazzes up the AI...